Abstract
BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) stabilizes oxyhaemoglobin, causing a reversible left-shift of the oxygen saturation curve (OSC) and tissue hypoxia. The activity of mitomycin C (MMC) is enhanced by hypoxia. In this phase II study, 17 patients with metastatic colorectal cancer resistant to 5-fluorouracil (5-FU) received BW12C and MMC. BW12C was given as a bolus loading dose of 45 mg kg–1 over 1 h, followed by a maintenance infusion of 4 mg kg–1h–1 for 5 h. MMC 6 mg m–2 was administered over 15 min immediately after the BW12C bolus. The 15 evaluable patients had progressive disease after a median of 2 (range 1–4) cycles of chemotherapy. Haemoglobin electrophoresis 3 and 5 h after the BW12C bolus dose showed a fast moving band consistent with the BW12C-oxyhaemoglobin complex, accounting for approximately 50% of total haemoglobin. The predominant toxicities – nausea/vomiting and vein pain – were mild and did not exceed CTC grade 2. Liver31P magnetic resonance spectroscopy of patients with hepatic metastases showed no changes consistent with tissue hypoxia. The principle of combining a hypoxically activated drug with an agent that increases tissue hypoxia is clinically feasible, producing an effect equivalent to reducing tumour oxygen delivery by at least 50%. However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen. This could be related to drug resistance rather than a failure to enhance cytotoxicity. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adams GE, Barnes DW, du Boulay C, Loutit JF, Cole S, Sheldon PW, Stratford IJ, van den Aardweg GJ, Hopewell JW, White RD, Kneen G, Nethersell ABW and Edwards JC (1986) Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin: implications for therapy. Int J Radiat Oncol Biol Phys 12: 1299–1302
Adams GE, Hasan NM and Joiner MC (1997) The Klaas Breur Lecture. Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother Oncol 44: 101–109
Beddell CR, Goodford PJ, Kneen G, White RD, Wilkinson S and Wootton R (1984) Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol 82: 397–407
Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285–289
Brown JM (1998) The potential benefit of hypoxic cytotoxins in radio-oncology. Blood Perfusion and Micro-environment in Human Tumours: Implications for Clinical Radio-oncology, Brady LW, Heilmann H-P219–229, Springer-Verlag: Berlin
Buroker T, Kim PN, Groppe C, McCracken J, O’Bryan R, Panettiere F, Coltman C, Bottomley R, Wilson H, Bonnet J, Thigpen T, Vaitkevicius VK, Hoogstraten B and Heilbrun L (1978) 5-FU infusion with mitomycin C versus 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study. Cancer 42: 1228–1233
Cole S and Robbins L (1989) Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069. Radiother Oncol 16: 235–243
Dennis IF, Ramsay JR, Workman P and Bleehen NM (1993) Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer. Cancer Chemother Pharmacol 32: 67–72
Dixon RM (1996) Phosphatidylethanolamine synthesis in the normal and lymphomatous mouse liver; a 13C NMR study. Anticancer Res 16: 1351–1356
Dixon RM, Angus PW, Rajagopalan B and Radda GK (1991) Abnormal phosphomonoester signals in 31P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy. Br J Cancer 63: 953–958
Dixon RM, Angus PW, Rajagopalan B and Radda GK (1992) 31P magnetic resonance spectroscopy detects a functional abnormality in liver metabolism after acetaminophen poisoning. Hepatology 16: 943–948
Falk SJ, Ramsay JR, Ward R, Miles K, Dixon AK and Bleehen NM (1994) BW12C perturbs normal and tumour tissue oxygenation and blood flow in man. Radiother Oncol 32: 210–217
Fitzharris P, McLean AE, Sparks RG, Weatherley BC, White RD and Wooton R (1985) The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. Br J Clin Pharmacol 19: 471–481
Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. Journal of the National Cancer Institute 88: 259–269
Gehan A (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353
Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L and Bokemeyer C (1998) Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 9: 427–431
Hochachka PW, Buck LT, Doll CJ and Land SC (1996) Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93: 9493–9498
Honess DJ, Hu DE and Bleehen NM (1991) BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice. Br J Cancer 64: 715–722
Honess DJ, Nethersell AB and Bleehen NM (1992) In vitro and in vivo studies using BW12C: toxicity, haemoglobin modification and effects on the radiosensitivity of normal marrow and RIF-1 tumours in mice. Int J Radiat Biol 61: 83–94
Lehmann H and Huntsman RG (1966). Man’s Haemoglobins, North Holland Publishing Company: Amsterdam
Migeod F, Gerlach D, Kress M, Hoffmann W, Farroukh R and Seeber S (1988) Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C. Onkologie 2: 14–20
Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T and Tsuruo T (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Research 56: 2823–2826
Negendank W (1992) Studies of human tumors by MRS: a review. NMR Biomed 5: 303–324
Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12: 119–134
Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, Radda GK and Harris AL (1993) A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. Cancer Res 53: 5649–5653
Plumb JA and Workman P (1994) Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56: 134–139
Richards F, Case LD, White DR, Muss HB, Spurr CL, Jackson DV, Cooper MR, Zekan P, Cruz J and Stuart JJ (1986) Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol 4: 565–570
Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R and Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995–1001
Ruiz-Cabello J and Cohen JS (1992) Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 5: 226–233
Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ and Rockwell S (1994) Mitomycin C: a prototype bioreductive agent. Oncol Res 6: 501–508
Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73–82
Zaniboni A, Meriggi F, Alghisi A, Mutti S, Distefano L, Rizzi A, Bettini L, Simoncini E, Marpicati P and Montini E (1995) Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study. Tumori 81: 435–437
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Propper, D., Levitt, N., O’Byrne, K. et al. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer 82, 1776–1782 (2000). https://doi.org/10.1054/bjoc.2000.1138
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1138